ABBV-075
货号：
21033-500ug 基本售价：
350.0 元 规格：
500 ug
产品信息
概述| 货号 | 21033-500ug |
| 描述 | ABBV-075 is a potent inhibitor of the bromodomain and extra terminal domain (BET) family of proteins that is selective for the bromodomain-containing proteins (BRD) BRD2, BRD4, and BRDT (Kis = 1-2.2 nM) over BRD3 (Ki = 12.2 nM) and against a panel of 18 BRD proteins.1 It inhibits BRD4 recruitment to androgen receptor-occupied gene enhancer sites leading to growth inhibition in androgen receptor-dependent prostate cancer cells.2 ABBV-075 halts the cell cycle in the G1 phase and induces apoptosis in prostate cancer cells as well as patient-derived acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.3 It is also efficacious in many xenograft mouse models including lung and prostate cancers, AML, and multiple myeloma.1,2,3 Formulations containing ABBV-075 are in clinical trials for the treatment of advanced hematologic malignancies and solid tumors. |
| 别名 | Mivebresib; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Sarthy, A.,Li, L.,Albpert, D.H., et al. Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications. Cancer Res. 76 (14 Suppl), (2016).
2.Faivre, E.J.,Wilcox, D.,Lin, X., et al. Exploitation of castration-resistant prostate cancer transcription factor dependencies by the novel BET inhibitor ABBV-075. Mol. Cancer Res. 15(1), 35-44 (2017).
3.Bui, M.H.,Lin, X.,Albert, D.H., et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 77(11), 2976-2989 (2017).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 459.5 |
| 分子式 | C22H19F2N3O4S |
| CAS号 | 1445993-26-9 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
